Prostate cancer adverse pathology reclassification in patients undergoing active surveillance in a long-term follow-up series

Uro-Oncology

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

J Urol.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW

doi: 10.1016/j.juro.2018.07.065.

Uro-Oncology

Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance

BJU Int.

Schwen ZR, Mamawala M, Tosoian JJ, Druskin SC, Ross AE, Sokoll LJ, Epstein JI, Carter HB, Gorin MA, Pavlovich CP

doi: 10.1111/bju.15101.

Uro-Oncology

A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance

J Urol.

Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR

doi: 10.1097/JU.0000000000000290

Erectile and Sexual Functions and DysfunctionsUrinary IncontinenceUro-Oncology

Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade

Cancer Med.

Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL

doi: 10.1002/cam4.1103.

Uro-Oncology

Active surveillance outcomes in prostate cancer patients: the use of transperineal template-guided mapping biopsy for patient selection

World J Urol.

Merrick GS, Tennant A, Fiano R, Bennett A, Anderson R, Galbreath R, Butler WM, Adamovich E

doi: 10.1007/s00345-019-02695-w.

Uro-Oncology

Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients

BJU Int.

Tomer A, Nieboer D, Roobol MJ, Bjartell A, Steyerberg EW, Rizopoulos D, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium

doi: 10.1111/bju.15136.

Uro-Oncology

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes

Eur Urol.

Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y

doi: 10.1016/j.eururo.2018.01.017.

Uro-Oncology

Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer

Prostate Cancer Prostatic Dis.

Nair SM, Peters M, Kurver P, Lavi A, Verhoeff JJC, van der Voort van Zyp JRN, van Son MJ, Chin JL

doi: 10.1038/s41391-020-00265-5.

Uro-OncologyPregnancy and Childbirth

Qualitative study on decision-making by prostate cancer physicians during active surveillance

BJU Int.

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E

doi: 10.1111/bju.13651.

Related content

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance

A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance

Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade

Active surveillance outcomes in prostate cancer patients: the use of transperineal template-guided mapping biopsy for patient selection

Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes

Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer

Qualitative study on decision-making by prostate cancer physicians during active surveillance